Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LEXX Stock Forecast 2025-2026
$1.06
Current Price
$23.56M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to LEXX Price Targets
+466.0%
To High Target of $6.00
+466.0%
To Median Target of $6.00
+277.4%
To Low Target of $4.00
LEXX Price Momentum
-2.8%
1 Week Change
+1.9%
1 Month Change
-55.3%
1 Year Change
-49.5%
Year-to-Date Change
-59.4%
From 52W High of $2.61
+36.8%
From 52W Low of $0.77
📊 TOP ANALYST CALLS
Did LEXX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Lexaria is one of their latest high-conviction picks.
Latest LEXX Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, LEXX has a bullish consensus with a median price target of $6.00 (ranging from $4.00 to $6.00). The overall analyst rating is N/A (N/A/10). Currently trading at $1.06, the median forecast implies a 466.0% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 277.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LEXX Analyst Ratings
2
Buy
0
Hold
0
Sell
LEXX Price Target Range
Low
$4.00
Average
$6.00
High
$6.00
Current: $1.06
Latest LEXX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LEXX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 29, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $4.00 |
| Jul 1, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $5.00 |
| Jan 24, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $7.00 |
| Dec 2, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $10.00 |
| Nov 25, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $10.00 |
| Jul 18, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $10.00 |
| Jul 10, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $10.00 |
| Mar 5, 2024 | Maxim Group | Michael Okunewitch | Buy | Maintains | $12.00 |
| Jul 21, 2023 | Maxim Group | Michael Okunewitch | Buy | Initiates | $2.00 |
Lexaria Bioscience Corp. (LEXX) Competitors
The following stocks are similar to Lexaria based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lexaria Bioscience Corp. (LEXX) Financial Data
Valuation Metrics
Market Cap
$23.56M
Enterprise Value
$21.31M
P/E Ratio
N/A
PEG Ratio
-2.7x
Price/Sales
33.4x
Growth & Margins
Revenue Growth (YoY)
+107.1%
Gross Margin
+100.0%
Operating Margin
-1,422.3%
Net Margin
+99.6%
EPS Growth
+107.1%
Financial Health
Cash/Price Ratio
+8.4%
Current Ratio
2.3x
Debt/Equity
4.2x
ROE
-232.2%
ROA
-111.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lexaria Bioscience Corp. (LEXX) Business Model
About Lexaria Bioscience Corp.
What They Do
Biotechnology company enhancing bioactive compound delivery.
Business Model
Lexaria Bioscience Corp. generates revenue by utilizing its proprietary DehydraTECH platform to improve the oral absorption of bioactive compounds like cannabinoids and nicotine. The company partners with various organizations across pharmaceuticals, nutraceuticals, and consumer goods to develop products that leverage its technology, thereby monetizing its innovative delivery systems.
Additional Information
Lexaria's focus on bioavailability and taste masking aligns with the growing demand for next-generation wellness products. By operating at the intersection of drug development and consumer health, the company is well-positioned to capitalize on emerging markets for efficient delivery systems of bioactive substances.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
7
CEO
Mr. Richard C. Christopher
Country
Canada
IPO Year
2021
Website
lexariabioscience.comLexaria Bioscience Corp. (LEXX) Latest News & Analysis
Latest News
Quick Summary
Lexaria Bioscience Corp. has extended its Material Transfer Agreement with a pharmaceutical company until April 30, 2026, for evaluating its DehydraTECHTM technology based on data from an Australian study.
Why It Matters
The extension of the MTA suggests ongoing interest from PharmaCO in Lexaria's technology, potentially signaling future partnerships or advancements, which could positively impact stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Lexaria Bioscience Corp. (NASDAQ: LEXX) has engaged a strategic advisory firm for new business development and received 4 new patents for its DehydraTECH technology in the pharmaceutical sector.
Why It Matters
Lexaria's engagement with a business development firm and new patents enhance its growth potential and market position, indicating possible future revenue increases that could attract investors.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Lexaria Bioscience Corp. closed a registered direct offering of 2.67 million shares at $1.50 each and issued unregistered warrants for the same amount of shares.
Why It Matters
Lexaria's direct stock offering and concurrent warrants can dilute existing shares, impacting stock value. The funding may enhance development but also signals potential cash flow needs.
Source: Accesswire
Market Sentiment:
Neutral
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2 months ago
Quick Summary
Lexaria Bioscience Corp. (NASDAQ:LEXX) announced a registered direct offering of 2.67 million shares at $1.50 each, along with unregistered warrants at $1.37. Closing expected by September 29, 2025.
Why It Matters
Lexaria Bioscience's direct offering and concurrent private placement indicate a capital raise, impacting share dilution and potential future stock performance. The terms of the warrants may influence investor sentiment.
Source: TheNewswire
Market Sentiment:
Neutral
Quick Summary
Lexaria Bioscience Corp. (Nasdaq: LEXX) reported successful results from a study showing that its DehydraTECH processing may enhance the brain biodistribution of semaglutide, potentially improving safety and efficacy.
Why It Matters
The successful study on enhanced GLP-1 drug delivery by Lexaria may lead to improved safety and efficacy, potentially boosting market competitiveness and increasing investor interest in the company's stock.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) will present at the H.C. Wainwright Global Investment Conference from September 8-10, 2025, with a presentation available online from September 5.
Why It Matters
Lexaria's participation in a major investment conference highlights its visibility and potential growth opportunities, which can attract investor interest and influence stock performance.
Source: TheNewswire
Market Sentiment:
Neutral
Frequently Asked Questions About LEXX Stock
What is Lexaria Bioscience Corp.'s (LEXX) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Lexaria Bioscience Corp. (LEXX) has a median price target of $6.00. The highest price target is $6.00 and the lowest is $4.00.
Is LEXX stock a good investment in 2026?
According to current analyst ratings, LEXX has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LEXX stock?
Wall Street analysts predict LEXX stock could reach $6.00 in the next 12 months. This represents a 466.0% increase from the current price of $1.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lexaria Bioscience Corp.'s business model?
Lexaria Bioscience Corp. generates revenue by utilizing its proprietary DehydraTECH platform to improve the oral absorption of bioactive compounds like cannabinoids and nicotine. The company partners with various organizations across pharmaceuticals, nutraceuticals, and consumer goods to develop products that leverage its technology, thereby monetizing its innovative delivery systems.
What is the highest forecasted price for LEXX Lexaria Bioscience Corp.?
The highest price target for LEXX is $6.00 from at , which represents a 466.0% increase from the current price of $1.06.
What is the lowest forecasted price for LEXX Lexaria Bioscience Corp.?
The lowest price target for LEXX is $4.00 from Yi Chen at HC Wainwright & Co., which represents a 277.4% increase from the current price of $1.06.
What is the overall LEXX consensus from analysts for Lexaria Bioscience Corp.?
The overall analyst consensus for LEXX is bullish. Out of 2 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are LEXX stock price projections?
Stock price projections, including those for Lexaria Bioscience Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 5:39 PM UTC